{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T09:09:51Z","timestamp":1795165791186,"version":"4.10.3"},"reference-count":135,"publisher":"Oxford University Press (OUP)","issue":"31","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020 research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is not a dichotomous disease trait. Technological innovations enable long-term rhythm monitoring in many patients and can estimate AF burden. These technologies are already used to detect and monitor AF. This review describes the relation between AF burden and outcomes and potential effects of AF burden reduction. A lower AF burden is associated with a lower risk of stroke and heart failure in patients with AF: stroke risk without anticoagulation is lower in patients with device-detected AF and a low AF burden (stroke rate 1%\/year) than in patients with persistent and permanent AF (stroke rate 3%\/year). Paroxysmal AF shows intermediate stroke rates (2%\/year). Atrial fibrillation burden\u2013reducing interventions can reduce cardiovascular outcomes in patients with AF: early rhythm control reduces cardiovascular events including stroke and heart failure in patients with recently diagnosed AF and cardiovascular conditions. In patients with heart failure and AF, early rhythm control and AF ablation, interventions that reduce AF burden, reduce mortality and heart failure events. Recent technological innovations allow to estimate AF burden in clinical care, creating opportunities and challenges. While evidence remains limited, the existing data already suggest that AF burden reduction could be a therapeutic goal. In addition to anticoagulation and treatment of cardiovascular conditions, AF burden reduction emerges as a therapeutic goal. Future research will define the AF burden that constitutes a relevant risk of stroke and heart failure. Technologies quantifying AF burden need careful validation to advance the field.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehae373","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T15:58:04Z","timestamp":1717084684000},"page":"2824-2838","source":"Crossref","is-referenced-by-count":165,"title":["Atrial fibrillation burden: a new outcome predictor and therapeutic target"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-1341","authenticated-orcid":false,"given":"Nina","family":"Becher","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf , Martinistrasse 52, 20246 Hamburg , Germany"},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site Hamburg\/Kiel\/Luebeck , Postdamer Str. 58, 10785 Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-6396","authenticated-orcid":false,"given":"Andreas","family":"Metzner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf , Martinistrasse 52, 20246 Hamburg , Germany"},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site Hamburg\/Kiel\/Luebeck , Postdamer Str. 58, 10785 Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7351-0621","authenticated-orcid":false,"given":"Tobias","family":"Toennis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf , Martinistrasse 52, 20246 Hamburg , Germany"},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site Hamburg\/Kiel\/Luebeck , Postdamer Str. 58, 10785 Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0197","authenticated-orcid":false,"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf , Martinistrasse 52, 20246 Hamburg , Germany"},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site Hamburg\/Kiel\/Luebeck , Postdamer Str. 58, 10785 Berlin , Germany"},{"name":"Institute of Cardiovascular Sciences, University of Birmingham , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7170-9509","authenticated-orcid":false,"given":"Renate B","family":"Schnabel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf , Martinistrasse 52, 20246 Hamburg , Germany"},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site Hamburg\/Kiel\/Luebeck , Postdamer Str. 58, 10785 Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"2024081616503707900_ehae373-B1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/europace\/euaa279","article-title":"Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET\/EHRA Consensus Conference","volume":"23","author":"Fabritz","year":"2021","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCULATIONAHA.121.055018","article-title":"Atrial fibrillation and dementia: a report from the AF-SCREEN international collaboration","volume":"145","author":"Rivard","year":"2022","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B4","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1093\/eurheartj\/ehaa726","article-title":"Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study","volume":"41","author":"Kim","year":"2020","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/eurheartj\/ehac692","article-title":"Healthcare utilization and quality of life for atrial fibrillation burden: the CIRCA-DOSE study","volume":"44","author":"Andrade","year":"2023","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.2023.14685","article-title":"Atrial fibrillation catheter ablation vs medical therapy and psychological distress: a randomized clinical trial","volume":"330","author":"Al-Kaisey","year":"2023","journal-title":"JAMA"},{"key":"2024081616503707900_ehae373-B7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"2024081616503707900_ehae373-B8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2024081616503707900_ehae373-B9","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B10","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/eurheartj\/ehab593","article-title":"Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial","volume":"43","author":"Willems","year":"2022","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B11","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1093\/eurheartj\/ehac471","article-title":"Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial","volume":"43","author":"Eckardt","year":"2022","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/eurheartj\/ehad771","article-title":"Anticoagulation with edoxaban in patients with long atrial high-rate episodes \u226524 hours","volume":"45","author":"Becher","year":"2024","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/ehjdh\/ztac067","article-title":"Smartphone and wearable detected atrial arrhythmias in older adults: results of a fully digital European case finding study","volume":"3","author":"Fabritz","year":"2022","journal-title":"Eur Heart J Digit Health"},{"key":"2024081616503707900_ehae373-B16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41591-022-01979-w","article-title":"Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial","volume":"28","author":"Rizas","year":"2022","journal-title":"Nat Med"},{"key":"2024081616503707900_ehae373-B17","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2589-7500(21)00253-3","article-title":"Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial","volume":"4","author":"Bauer","year":"2022","journal-title":"Lancet Digit Health"},{"key":"2024081616503707900_ehae373-B18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euac062","article-title":"Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET\/EHRA consensus conference","volume":"25","author":"Schnabel","year":"2023","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B19","doi-asserted-by":"crossref","first-page":"82N","DOI":"10.1016\/S0002-9149(98)00589-X","article-title":"The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation","volume":"82","author":"Kerr","year":"1998","journal-title":"Am J Cardiol"},{"key":"2024081616503707900_ehae373-B20","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1161\/CIRCULATIONAHA.106.644484","article-title":"Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study","volume":"115","author":"Jahangir","year":"2007","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/eurheartj\/ehn139","article-title":"Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation","volume":"29","author":"Nieuwlaat","year":"2008","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/europace\/euaa123","article-title":"Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V","volume":"22","author":"De With","year":"2020","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B23","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/heartjnl-2017-312569","article-title":"Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes","volume":"104","author":"Schnabel","year":"2018","journal-title":"Heart"},{"key":"2024081616503707900_ehae373-B24","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/j.jacc.2014.04.019","article-title":"Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices","volume":"63","author":"Charitos","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024081616503707900_ehae373-B25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCEP.111.965178","article-title":"Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial","volume":"5","author":"Goette","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2024081616503707900_ehae373-B26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/heartjnl-2022-321027","article-title":"Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation","volume":"109","author":"Nguyen","year":"2022","journal-title":"Heart"},{"key":"2024081616503707900_ehae373-B27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/europace\/euab200","article-title":"Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST-AFNET 4 trial","volume":"24","author":"Metzner","year":"2022","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B28","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1093\/eurheartj\/ehad247","article-title":"Impact of early versus delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences","volume":"44","author":"Kalman","year":"2023","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B29","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/j.jacc.2019.09.050","article-title":"Natural history of subclinical atrial fibrillation detected by implanted loop recorders","volume":"74","author":"Diederichsen","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024081616503707900_ehae373-B30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12872-020-01453-w","article-title":"Brief episodes of rapid irregular atrial activity (micro-AF) are a risk marker for atrial fibrillation: a prospective cohort study","volume":"20","author":"Fredriksson","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2024081616503707900_ehae373-B31","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.109.874982","article-title":"Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke","volume":"121","author":"Binici","year":"2010","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B32","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes. Reply","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B33","doi-asserted-by":"crossref","first-page":"euad166","DOI":"10.1093\/europace\/euad166","article-title":"The influence of atrial high-rate episodes on stroke and cardiovascular death: an update","volume":"25","author":"Toennis","year":"2023","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B34","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.117.028845","article-title":"Subclinical atrial fibrillation in older patients","volume":"136","author":"Healey","year":"2017","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B35","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B36","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials","volume":"149","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2009","article-title":"Pathophysiological mechanisms of atrial fibrillation: a translational appraisal","volume":"91","author":"Schotten","year":"2011","journal-title":"Physiol Rev"},{"key":"2024081616503707900_ehae373-B38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1540-8167.2008.01320.x","article-title":"Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events","volume":"20","author":"Botto","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2024081616503707900_ehae373-B39","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.119.041303","article-title":"Stroke risk as a function of atrial fibrillation duration and CHA(2)DS(2)-VASc score","volume":"140","author":"Kaplan","year":"2019","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B40","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehae225","article-title":"Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with and without oral anticoagulation in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial","volume":"45","author":"Lip","year":"2024","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B41","doi-asserted-by":"crossref","first-page":"euae070","DOI":"10.1093\/europace\/euae070","article-title":"Longer and better lives for patients with atrial fibrillation: the 9th AFNET\/EHRA consensus conference","volume":"26","author":"Linz","year":"2024","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2019.04.055","article-title":"Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: the West Birmingham Atrial Fibrillation Project","volume":"292","author":"Li","year":"2019","journal-title":"Int J Cardiol"},{"key":"2024081616503707900_ehae373-B43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurheartj\/ehu307","article-title":"Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES","volume":"36","author":"Vanassche","year":"2015","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B44","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/eurheartj\/eht491","article-title":"Device-detected atrial fibrillation and risk for stroke: an analysis of &gt;10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices)","volume":"35","author":"Boriani","year":"2014","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B45","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B46","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCEP.109.849638","article-title":"The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study","volume":"2","author":"Glotzer","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2024081616503707900_ehae373-B47","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(21)01637-8","article-title":"Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial","volume":"398","author":"Svennberg","year":"2021","journal-title":"Lancet"},{"key":"2024081616503707900_ehae373-B48","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0140-6736(21)01698-6","article-title":"Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial","volume":"398","author":"Svendsen","year":"2021","journal-title":"Lancet"},{"key":"2024081616503707900_ehae373-B49","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/CIRCRESAHA.121.319718","article-title":"Effects of atrial fibrillation on the human ventricle","volume":"130","author":"Pabel","year":"2022","journal-title":"Circ Res"},{"key":"2024081616503707900_ehae373-B50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00395-022-00949-0","article-title":"Tachycardiomyopathy entails a dysfunctional pattern of interrelated mitochondrial functions","volume":"117","author":"Paulus","year":"2022","journal-title":"Basic Res Cardiol"},{"key":"2024081616503707900_ehae373-B51","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1093\/eurheartj\/ehz782","article-title":"Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation","volume":"40","author":"Willems","year":"2019","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B52","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa0708234","article-title":"Pulmonary-vein isolation for atrial fibrillation in patients with heart failure","volume":"359","author":"Khan","year":"2008","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B53","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMoa041018","article-title":"Catheter ablation for atrial fibrillation in congestive heart failure","volume":"351","author":"Hsu","year":"2004","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B54","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B55","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1093\/eurheartj\/ehy421","article-title":"Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction","volume":"39","author":"Santema","year":"2018","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B56","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.hrthm.2021.01.021","article-title":"Atrial fibrillation burden and heart failure: data from 39,710 individuals with cardiac implanted electronic devices","volume":"18","author":"Steinberg","year":"2021","journal-title":"Heart Rhythm"},{"key":"2024081616503707900_ehae373-B58","first-page":"3250","article-title":"Atrial fibrillation in heart failure: what should we do?","volume":"36","author":"Kotecha","year":"2015","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B60","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMoa2306037","article-title":"Catheter ablation in end-stage heart failure with atrial fibrillation","volume":"389","author":"Sohns","year":"2023","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow\u2019s triad revisited","volume":"373","author":"Watson","year":"2009","journal-title":"Lancet"},{"key":"2024081616503707900_ehae373-B62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/eurheartj\/ehw119","article-title":"Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation","volume":"38","author":"Spronk","year":"2017","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B63","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2024081616503707900_ehae373-B64","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","article-title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","volume":"384","author":"Whitlock","year":"2021","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B65","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/eurheartj\/ehad744","article-title":"Atrial fibrillation first detected after stroke: is timing and detection intensity relevant for stroke risk?","volume":"45","author":"Sposato","year":"2024","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B66","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1093\/eurheartj\/ehm358","article-title":"Outcome parameters for trials in atrial fibrillation: executive summary: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)","volume":"28","author":"Kirchhof","year":"2007","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B67","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B68","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/eurheartj\/ehz304","article-title":"Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation","volume":"40","author":"Friberg","year":"2019","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B69","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/europace\/eut286","article-title":"The effect of a nurse-led integrated chronic care approach on quality of life in patients with atrial fibrillation","volume":"16","author":"Hendriks","year":"2014","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B70","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/eurheartj\/ehw285","article-title":"Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial","volume":"37","author":"Kuck","year":"2016","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B71","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/jama.2019.0692","article-title":"Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial","volume":"321","author":"Mark","year":"2019","journal-title":"JAMA"},{"key":"2024081616503707900_ehae373-B72","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2020.23138","article-title":"Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial","volume":"324","author":"Kotecha","year":"2020","journal-title":"JAMA"},{"key":"2024081616503707900_ehae373-B73","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.2019.0335","article-title":"Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial","volume":"321","author":"Blomstrom-Lundqvist","year":"2019","journal-title":"JAMA"},{"key":"2024081616503707900_ehae373-B74","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/europace\/euab029","article-title":"Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation","volume":"23","author":"Kuniss","year":"2021","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B75","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2029554","article-title":"Cryoballoon ablation as initial therapy for atrial fibrillation","volume":"384","author":"Wazni","year":"2021","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2212540","article-title":"Progression of atrial fibrillation after cryoablation or drug therapy","volume":"388","author":"Andrade","year":"2023","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B77","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1113566","article-title":"Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation","volume":"367","author":"Cosedis Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B78","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/eurheartj\/ehad572","article-title":"Atrial fibrillation progression after cryoablation versus radiofrequency ablation: the CIRCA-DOSE trial","volume":"45","author":"Andrade","year":"2024","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B79","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ahj.2012.02.015","article-title":"Progression of atrial fibrillation in the registry on cardiac rhythm disorders assessing the control of atrial fibrillation cohort: clinical correlates and the effect of rhythm-control therapy","volume":"163","author":"De Vos","year":"2012","journal-title":"Am Heart J"},{"key":"2024081616503707900_ehae373-B80","doi-asserted-by":"crossref","first-page":"e011237","DOI":"10.1161\/CIRCEP.122.011237","article-title":"Economic and health value of delaying atrial fibrillation progression using radiofrequency catheter ablation","volume":"16","author":"Berman","year":"2023","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2024081616503707900_ehae373-B81","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/europace\/euaa298","article-title":"Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST)","volume":"23","author":"Kuck","year":"2021","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B82","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/eurheartj\/ehx739","article-title":"Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial","volume":"39","author":"Rienstra","year":"2018","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B83","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/europace\/euab270","article-title":"Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial","volume":"24","author":"Nguyen","year":"2022","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B84","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1136\/heartjnl-2022-321196","article-title":"Eligibility for early rhythm control in patients with atrial fibrillation in the UK biobank","volume":"108","author":"Kany","year":"2022","journal-title":"Heart"},{"key":"2024081616503707900_ehae373-B85","doi-asserted-by":"crossref","first-page":"n991","DOI":"10.1136\/bmj.n991","article-title":"Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study","volume":"373","author":"Kim","year":"2021","journal-title":"BMJ"},{"key":"2024081616503707900_ehae373-B86","doi-asserted-by":"crossref","first-page":"e011585","DOI":"10.1161\/CIRCEP.122.011585","article-title":"Outcomes of early rhythm control therapy in patients with atrial fibrillation and a high comorbidity burden in large real-world cohorts","volume":"16","author":"Dickow","year":"2023","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2024081616503707900_ehae373-B87","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser","year":"2009","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B88","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/CIRCULATIONAHA.109.875252","article-title":"Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation\/atrial flutter","volume":"120","author":"Connolly","year":"2009","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B89","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Wyse","year":"2002","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B90","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation","volume":"347","author":"Van Gelder","year":"2002","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B91","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.CIR.0000121736.16643.11","article-title":"Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study","volume":"109","author":"Corley","year":"2004","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B92","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa0708789","article-title":"Rhythm control versus rate control for atrial fibrillation and heart failure","volume":"358","author":"Roy","year":"2008","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B93","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B94","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/CIRCULATIONAHA.122.060274","article-title":"Early rhythm control in patients with atrial fibrillation and high comorbidity burden","volume":"146","author":"Rillig","year":"2022","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B95","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B96","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B97","first-page":"1303","article-title":"Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry","volume":"38","author":"Arbelo","year":"2017","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B98","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/eurheartj\/ehy176","article-title":"Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation","volume":"39","author":"Kirchhof","year":"2018","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B99","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation","volume":"384","author":"Andrade","year":"2021","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B100","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1093\/eurheartj\/ehad514","article-title":"Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management","volume":"44","author":"Moons","year":"2023","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B101","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B102","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B103","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B104","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"Diener","year":"2019","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy","volume":"331","author":"Kamel","year":"2024","journal-title":"JAMA"},{"key":"2024081616503707900_ehae373-B106","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1474-4422(21)00067-3","article-title":"Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study","volume":"20","author":"Haeusler","year":"2021","journal-title":"Lancet Neurol"},{"key":"2024081616503707900_ehae373-B107","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1474-4422(23)00326-5","article-title":"Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack","volume":"23","author":"Sposato","year":"2024","journal-title":"Lancet Neurol"},{"key":"2024081616503707900_ehae373-B108","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1474-4422(15)70027-X","article-title":"Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis","volume":"14","author":"Sposato","year":"2015","journal-title":"Lancet Neurol"},{"key":"2024081616503707900_ehae373-B109","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamaneurol.2019.0617","article-title":"Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial","volume":"76","author":"Healey","year":"2019","journal-title":"JAMA Neurol"},{"key":"2024081616503707900_ehae373-B110","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1161\/CIRCULATIONAHA.121.055176","article-title":"Predictors of atrial fibrillation development in patients with embolic stroke of undetermined source: an analysis of the RE-SPECT ESUS trial","volume":"144","author":"Bahit","year":"2021","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B111","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.113.007825","article-title":"Temporal relationship between subclinical atrial fibrillation and embolic events","volume":"129","author":"Brambatti","year":"2014","journal-title":"Circulation"},{"key":"2024081616503707900_ehae373-B112","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamacardio.2021.3702","article-title":"Temporal association between episodes of atrial fibrillation and risk of ischemic stroke","volume":"6","author":"Singer","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2024081616503707900_ehae373-B113","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/eurheartj\/ehx731","article-title":"Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis","volume":"39","author":"Mahajan","year":"2018","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ahj.2023.06.016","article-title":"Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism\u2014the Find-AF 2 study\u2014rationale and design","volume":"265","author":"Uhe","year":"2023","journal-title":"Am Heart J"},{"key":"2024081616503707900_ehae373-B115","doi-asserted-by":"crossref","first-page":"e073470","DOI":"10.1136\/bmjopen-2023-073470","article-title":"Multicentre, national, investigator-initiated, randomised, parallel-group, register-based superiority trial to compare extended ECG monitoring versus standard ECG monitoring in elderly patients with ischaemic stroke or transient ischaemic attack and the effect on stroke, death and intracerebral bleeding: the AF SPICE protocol","volume":"13","author":"Engdahl","year":"2023","journal-title":"BMJ Open"},{"key":"2024081616503707900_ehae373-B116","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2024081616503707900_ehae373-B117","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/heartjnl-2016-309781","article-title":"Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial","volume":"103","author":"Nielsen","year":"2017","journal-title":"Heart"},{"key":"2024081616503707900_ehae373-B118","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1540-8167.2011.02035.x","article-title":"Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation","volume":"22","author":"Bunch","year":"2011","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2024081616503707900_ehae373-B119","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jacc.2009.11.039","article-title":"The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation","volume":"55","author":"Themistoclakis","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2024081616503707900_ehae373-B120","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ahj.2017.12.007","article-title":"The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial","volume":"197","author":"Verma","year":"2018","journal-title":"Am Heart J"},{"key":"2024081616503707900_ehae373-B121","doi-asserted-by":"crossref","first-page":"e022833","DOI":"10.1161\/JAHA.121.022833","article-title":"Interactions between atrial fibrillation and natriuretic peptide in predicting heart failure hospitalization or cardiovascular death","volume":"11","author":"Brady","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024081616503707900_ehae373-B122","doi-asserted-by":"crossref","first-page":"euae028","DOI":"10.1093\/europace\/euae028","article-title":"Disturbed atrial metabolism, shear stress, and cardiac load after AF ablation: AXAFA biomolcules study","volume":"26","author":"Chua","year":"2024","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B123","first-page":"370","article-title":"B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation","volume":"105","author":"Inohara","year":"2019","journal-title":"Heart"},{"key":"2024081616503707900_ehae373-B124","doi-asserted-by":"crossref","first-page":"16743","DOI":"10.1038\/s41598-023-42331-7","article-title":"An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions","volume":"13","author":"Chua","year":"2023","journal-title":"Sci Rep"},{"key":"2024081616503707900_ehae373-B125","doi-asserted-by":"crossref","first-page":"e139179","DOI":"10.1172\/jci.insight.139179","article-title":"Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation","volume":"5","author":"Reyat","year":"2020","journal-title":"JCI Insight"},{"key":"2024081616503707900_ehae373-B126","doi-asserted-by":"crossref","first-page":"e028255","DOI":"10.1161\/JAHA.122.028255","article-title":"Bone morphogenetic protein 10\u2014a novel biomarker to predict adverse outcomes in patients with atrial fibrillation","volume":"12","author":"Hennings","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2024081616503707900_ehae373-B127","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/eurheartj\/ehac632","article-title":"Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation","volume":"44","author":"Hijazi","year":"2023","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B128","doi-asserted-by":"crossref","first-page":"e1003405","DOI":"10.1371\/journal.pmed.1003405","article-title":"Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: a validation study","volume":"18","author":"Chua","year":"2021","journal-title":"PLoS Med"},{"key":"2024081616503707900_ehae373-B129","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/europace\/euw319","article-title":"Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design","volume":"19","author":"Engdahl","year":"2017","journal-title":"Europace"},{"key":"2024081616503707900_ehae373-B130","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/heartjnl-2021-319338","article-title":"Trends in the pharmacological management of atrial fibrillation in UK general practice 2008\u20132018","volume":"108","author":"Phillips","year":"2022","journal-title":"Heart"},{"key":"2024081616503707900_ehae373-B131","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/eurheartj\/ehac758","article-title":"Artificial intelligence to enhance clinical value across the spectrum of cardiovascular healthcare","volume":"44","author":"Gill","year":"2023","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B132","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/eurheartj\/ehac460","article-title":"A polygenic risk score predicts atrial fibrillation in cardiovascular disease","volume":"44","author":"Marston","year":"2023","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B133","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/eurheartj\/ehy815","article-title":"Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation","volume":"40","author":"Chua","year":"2019","journal-title":"Eur Heart J"},{"key":"2024081616503707900_ehae373-B134","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/jce.15866","article-title":"Pill-in-Pocket anticoagulation for stroke prevention in atrial fibrillation","volume":"34","author":"Peigh","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2024081616503707900_ehae373-B135","doi-asserted-by":"crossref","first-page":"e065066","DOI":"10.1136\/bmjopen-2022-065066","article-title":"Cluster randomised controlled trial of screening for atrial fibrillation in people aged 70 years and over to reduce stroke: protocol for the pilot study for the SAFER trial","volume":"12","author":"Williams","year":"2022","journal-title":"BMJ Open"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/31\/2824\/58838305\/ehae373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/31\/2824\/58838305\/ehae373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T12:51:38Z","timestamp":1723812698000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/31\/2824\/7702745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":135,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2024,7,2]]},"published-print":{"date-parts":[[2024,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae373","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,14]]},"published":{"date-parts":[[2024,7,2]]}}}